Drugs / SOT201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06163391 | May 2024 → Oct 2026 expected | metastatic neoplasm | SOTIO Biotech AG | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | SOTIO a.s. | Results SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting sotio.com ↗
Four patients have been treated so far and the treatment was well tolerated. |
| 2023-10-31 | SOTIO a.s. | Results SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting sotio.com ↗
Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06163391 ↗ |
| Action | Activate | “These immunocytokines spatiotemporally reinvigorate PD-1+ CD8+ tumor-infiltrating lymphocytes (TILs) via cis-activation and concomitantly activate the innate immunity via...” PMID 40250867 ↗ Apr 2025 |
| Modality | Protein / enzyme biologic | “SOT201 and its murine surrogate mSOT201 are novel cis-acting immunocytokines consisting of a humanized/murinized/, Fc-silenced anti-programmed cell death protein 1 (PD-1)...” PMID 40250867 ↗ Apr 2025 |